42 related articles for article (PubMed ID: 28228232)
1. Hormone receptor expression profile of low-grade serous ovarian cancers.
Buttarelli M; Mascilini F; Zannoni GF; Ciucci A; Martinelli E; Filippetti F; Scambia G; Ferrandina G; Gallo D
Gynecol Oncol; 2017 May; 145(2):352-360. PubMed ID: 28228232
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.
Kamal AM; Bulmer JN; DeCruze SB; Stringfellow HF; Martin-Hirsch P; Hapangama DK
Br J Cancer; 2016 Mar; 114(6):688-96. PubMed ID: 26930451
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
Oncotarget; 2017 May; 8(20):32848-32855. PubMed ID: 28416763
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Iyer RB; Malpica AL; Kavanagh JJ; Bodurka DC; Schmeler K; Deavers M
Gynecol Oncol; 2012 Jun; 125(3):661-6. PubMed ID: 22406638
[TBL] [Abstract][Full Text] [Related]
5. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
[TBL] [Abstract][Full Text] [Related]
7. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C
Gynecol Oncol; 2024 Apr; 186():42-52. PubMed ID: 38582027
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry.
Moh M; Puzyrenko A; Summey R; Rader JS; Herrera Cano GE; Gavina JV; Rui H; Sun Y; Hopp E
Int J Gynecol Pathol; 2024 Mar; ():. PubMed ID: 38661526
[TBL] [Abstract][Full Text] [Related]
9. Current concept of low-grade serous ovarian carcinoma.
Nakayama K; Razia S; Ishibashi T; Kyo S
Transl Cancer Res; 2024 Jan; 13(1):6-10. PubMed ID: 38410232
[No Abstract] [Full Text] [Related]
10. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
12. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Adam JP; Boumedien F; Letarte N; Provencher D
Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
[TBL] [Abstract][Full Text] [Related]
13. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Fernandez ML; Dawson A; Hoenisch J; Kim H; Bamford S; Salamanca C; DiMattia G; Shepherd T; Cremona M; Hennessy B; Anderson S; Volik S; Collins CC; Huntsman DG; Carey MS
Cancer Cell Int; 2019; 19():10. PubMed ID: 30636931
[TBL] [Abstract][Full Text] [Related]
14. Low-grade Serous Tumors: Are We Making Progress?
Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression in low grade serous ovarian cancer; clinical considerations in the diagnosis, treatment and surveillance of disease in a transgender male.
Smrz SA; Chapman G; Gordon J; Bagby C; Nascimento A; Ferguson L
Gynecol Oncol Rep; 2023 Jun; 47():101190. PubMed ID: 37152242
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.
Cheasley D; Fernandez ML; Köbel M; Kim H; Dawson A; Hoenisch J; Bittner M; Chiu DS; Talhouk A; Gilks CB; Jayawardana MW; Pishas KI; Mes-Masson AM; Provencher D; Nigam A; Hacker NF; Gorringe KL; Campbell IG; Carey MS
NPJ Precis Oncol; 2022 Jun; 6(1):47. PubMed ID: 35768582
[TBL] [Abstract][Full Text] [Related]
18. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
Shanta K; Nakayama K; Hossain MM; Razia S; Ishibashi T; Ishikawa M; Yamashita H; Kanno K; Sato S; Nakayama S; Otsuki Y; Kyo S
Curr Oncol; 2022 Jun; 29(6):4020-4033. PubMed ID: 35735430
[TBL] [Abstract][Full Text] [Related]
19. Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Langdon SP; Herrington CS; Hollis RL; Gourley C
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32580290
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research.
Gadducci A; Cosio S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
